Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “MIRAGEN THERAPEUTICS, INC.”

18 pharma patents match "MIRAGEN THERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 18
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 18 pharmaceutical patents matching "MIRAGEN THERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

18 results for “MIRAGEN THERAPEUTICS, INC.” · 30,257 patents in full index Clear search

  1. US 10337005

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    MIRAGEN THERAPEUTICS, INC. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted
  2. US 10316318

    Oligonucleotide compositions and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted
  3. US 10280422

    MiR-92 inhibitors and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted May 7, 2019 · Expires May 2, 2039

    granted
  4. US 10144930

    Inhibitors of MYH7B and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Dec 4, 2018 · Expires Nov 29, 2038

    granted
  5. US 10011833

    Bridged bicyclic nucleosides

    MIRAGEN THERAPEUTICS, INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  6. US 9994852

    Oligonucleotide compositions and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted
  7. US 9994847

    miR-29 mimics and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted
  8. US 9885042

    miR-92 inhibitors and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  9. US 9803202

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    MIRAGEN THERAPEUTICS, INC. · Granted Oct 31, 2017 · Expires Oct 26, 2037

    granted
  10. US 9771585

    miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)

    MIRAGEN THERAPEUTICS, INC. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  11. US 9752144

    Inhibitors of MYH7B and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  12. US 9752143

    Locked nucleic acid inhibitor of miR-145 and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  13. US 9416360

    Base modified oligonucleotides

    MIRAGEN THERAPEUTICS, INC. · Granted Aug 16, 2016 · Expires Aug 11, 2036

    granted
  14. US 9388408

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    MIRAGEN THERAPEUTICS, INC. · Granted Jul 12, 2016 · Expires Jul 7, 2036

    granted
  15. US 9376681

    miR-29 mimics and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Jun 28, 2016 · Expires Jun 23, 2036

    granted
  16. US 9163235

    Inhibitors of the miR-15 family of micro-RNAs

    MIRAGEN THERAPEUTICS, INC. · Granted Oct 20, 2015 · Expires Oct 15, 2035

    granted
  17. US 9012225

    Lipophilic polynucleotide conjugates

    MIRAGEN THERAPEUTICS, INC. · Granted Apr 21, 2015 · Expires Apr 16, 2035

    granted
  18. US 8642751

    MicroRNA inhibitors comprising locked nucleotides

    MIRAGEN THERAPEUTICS, INC. · Granted Feb 4, 2014 · Expires Jan 30, 2034

    granted